PTC Therapeutics (NASDAQ:PTCT) Insider Eric Pauwels Sells 1,789 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Eric Pauwels sold 1,789 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $76.95, for a total transaction of $137,663.55. Following the transaction, the insider owned 88,841 shares of the company’s stock, valued at approximately $6,836,314.95. The trade was a 1.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Eric Pauwels also recently made the following trade(s):

• On Wednesday, January 7th, Eric Pauwels sold 1,352 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total transaction of $104,752.96.
• On Friday, December 19th, Eric Pauwels sold 20,508 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.26, for a total transaction of $1,584,448.08.
• On Wednesday, December 17th, Eric Pauwels sold 40,290 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.43, for a total transaction of $3,039,074.70.
• On Thursday, December 18th, Eric Pauwels sold 3,202 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.06, for a total transaction of $240,342.12.

PTC Therapeutics Trading Down 0.5%

Shares of PTC Therapeutics stock opened at $76.85 on Friday. The business has a 50-day moving average price of $76.43 and a two-hundred day moving average price of $62.53. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50. The company has a market cap of $6.17 billion, a P/E ratio of 8.98 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The company had revenue of $211.01 million for the quarter, compared to the consensus estimate of $177.42 million. During the same period in the previous year, the business earned ($1.39) EPS. The firm’s revenue was up 7.2% compared to the same quarter last year. Equities research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Hedge Funds Weigh In On PTC Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in PTCT. Jefferies Financial Group Inc. purchased a new position in PTC Therapeutics in the third quarter valued at approximately $97,252,000. Hood River Capital Management LLC raised its stake in shares of PTC Therapeutics by 654.4% in the second quarter. Hood River Capital Management LLC now owns 636,502 shares of the biopharmaceutical company’s stock valued at $31,087,000 after buying an additional 552,130 shares during the period. State Street Corp lifted its position in shares of PTC Therapeutics by 22.1% during the 2nd quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock valued at $146,347,000 after buying an additional 541,558 shares during the last quarter. Palo Alto Investors LP grew its stake in shares of PTC Therapeutics by 112.2% during the 3rd quarter. Palo Alto Investors LP now owns 862,613 shares of the biopharmaceutical company’s stock worth $52,939,000 after acquiring an additional 456,144 shares during the period. Finally, Man Group plc increased its holdings in PTC Therapeutics by 157.4% in the 2nd quarter. Man Group plc now owns 671,513 shares of the biopharmaceutical company’s stock worth $32,797,000 after acquiring an additional 410,653 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on PTCT shares. Barclays increased their target price on shares of PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Cowen restated a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday, November 5th. Jefferies Financial Group increased their price target on PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Wells Fargo & Company boosted their price objective on PTC Therapeutics from $73.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $77.27.

PTC Therapeutics News Roundup

Here are the key news stories impacting PTC Therapeutics this week:

• Neutral Sentiment: Analysts maintain a consensus rating of “Hold” on PTCT, signaling muted broker enthusiasm and limited near-term upward catalyst from Wall Street. Article Title
• Neutral Sentiment: PTC reported an inducement grant of 300 restricted stock units for a new non-executive hire under Nasdaq Rule 5635(c)(4); a routine, small hire award with minimal direct financial impact but modest dilution. Article Title
• Negative Sentiment: A company director executed a sizable sale valued at $916,200, a notable insider disposition that can weigh on investor sentiment even if done for personal reasons. Article Title
• Negative Sentiment: Broad insider selling disclosed in SEC Form 4 filings: multiple senior executives (including CEO Matthew B. Klein, CFO Pierre Gravier, EVP Lee Golden, VP Mark Boulding, CAO Christine Utter and others) sold shares in early January. These trades—ranging from small lots to multi-thousand-share sales—represent notable reductions in insider positions and may signal profit-taking or diversification, which can pressure the stock until a clear operational/strategy signal offsets them. Representative filings: SEC Form 4

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.